L6 - Other good practices? Flashcards

1
Q

Advantages of Nanomedicines

A
  1. Effective in targeting difficult-to-reach sites (such as tumour sites
  2. Improved solubility, bioavailability & reduced side effects
  3. Achieve same therapeutic effect with smaller doses
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Name some examples of QbD/PATs?

A

NIR, Rama spectroscopy, X-ray diffraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

List the advantages and benefits of QbD/PAT

A
  1. Non destructive, unlike conventional QC
  2. Deeper process understanding, better control and better quality assurance of entire batch
  3. Real time release of products (instead of waiting to be released)
  4. Reduced post-approval submissions to regulator
  5. Cost-saving for industry
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

List the challenges of QbD/PAT implementation

A
  1. Requires deeper science and technological knowledge that personnel from regulations and industry may not be familiar with
  2. High Financial investment in PAT due to high initial capital outlay
  3. Companies’ old habits are difficult to change
  4. Manufacturers feel that PAT may reveal inadequacies and are discouraged to use it
  5. Regulators are not ready for QbD/PAT submissions as they are used to the old paradigm of QbT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are some of the limitations of QbT?

A
  • Product/batch only tested at the end of the manufacturing process
  • Can only test on a ‘representative sample size’
  • Tests are destructive
  • Can test only if the test method is specific, accurate and reliable
  • Defects are only picked up at the end of the manufacturing process so defective products cannot be rectified/reworked
  • QC tests not conducted and released in real-time, taking up expensive warehouse space
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are disadvantages of traditional batch manufacturing of tablets?

A
  • Intermediate products collected after each unit operation
  • Finished product collected at end of batch manufacturing
  • QC tests performed at off-line laboratories and finished products quarantined at warehouse
  • Total batch processing takes weeks, resulting in increased costs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Importance of inspecting API quality

A
  • APIs responsible for therapeutic effect of drug product
  • Without APIs, product is basically placebo
  • Bulk of APIs produced in Asia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are pharmaceutical excipients?

A

Substances which are re-combined with active pharmaceutical ingredients to form finished product

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Name some examples of single use technology

A
  • Single-use cell banking bags
  • Pre-packed chromatic columns and buffers
  • Single use syringes and injection ports
  • 3D printed valves
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are some things that are tested in SUTs?

A
  • Material compatibility
  • Extractables
  • Biocompatibility
  • Animal origins
  • Particulate control
  • Bioburden control
  • Absorption
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the role of GMP/GDP in compliance and vigilance in supply chains?

A
  1. Assure quality of API/products
  2. Deter Manipulation by unscrupulous supply chain players
  3. Detect Adulterated Products
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Name some benefits of ASEAN MRA on GMP inspection

A
  1. Avoid duplication of GM audits
  2. Save time, resources and cost
  3. Facilitate trade across ASEAN borders
  4. Quicker access to products by ASEAN patients
  5. Harmonised inspection system to that of PIC/S
  6. Increase attractiveness of ASEAN to investors from larger economies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is a register of LIS?

A

Listed Inspection service. Countries that are part of LIS can inspect for GMP/GDP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

As of now, what are the countries that are included in the ASEAN LIS?

A

Singapore, Malaysia, Indonesia, Thailand, Philippines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the current scope of ASEAN Sectoral MRA?

A

Finished dosage forms ONLY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What does ASEAN MRA on GMP inspection NOT include?

A
  1. Manufacture of APIs

2. Manufacture of Biologicals

17
Q

What are some advantages of continuous manufacturing?

A
  1. Integrated processes (hence fewer steps)
  2. Shorter batch processing time
  3. Smaller equipment and facilities (more flexible, reduce inventory, lower capital cost)
  4. On-line monitoring and QC via PAT (Higher QA level, more consistent quality, RTR)
  5. Overall cost reduction
18
Q

Why is GMP compliance and process control important at API manufacturing sites?

A
  1. It can ensure the QUALITY of APIs (e.g. particle size)
  2. It can ensure PURITY (e.g. enantiomers)
  3. It can ensure API supply chain integrity
19
Q

What are some issues posed by having an increased number of players in API and product supply chains?

A
  1. Potential points for interference of API/product

2. Falsified medicines

20
Q

Can excipients be regarded as inactive or inert ingredients?

A

No. Note that global supply chain can also affect the supply integrity of excipients

21
Q

One important property of a SUT

A

Materials that make up SUT must be inert

22
Q

What are some benefits of using SUTs?

A
  1. Better cross-contamination control = higher QA level
  2. “Flexible” manufacturing that requires less space = save time and cost
  3. Allow SUT usage in other pharmaceutical and healthcare sectors such as hospital pharmacies
23
Q

Steps in guideline development:

A
  1. Consensus building
  2. ICH parties consensus on technical document
  3. Regulatory consultation and discussion
  4. Adaptation of ICH harmonised guideline
  5. Implementation